Acro Biomedical (ACBM) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 14, 2023
Cover [Abstract]
Entity Registrant Name	ACRO BIOMEDICAL CO., LTD.
Entity Central Index Key	0001622996
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		60,042,000
Entity File Number	000-55643
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	47-1950356
Entity Address Address Line 1	12175 Visionary Way
Entity Address Address Line 2	Suite 1160
Entity Address City Or Town	Fishers
Entity Address State Or Province	IN
Entity Address Postal Zip Code	46038
City Area Code	317
Local Phone Number	286-6788
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 2,680	$ 5,852
Accounts receivable	498,500	638,500
Purchase deposit for inventory	12,000	12,000
Prepaid expenses	8,750	1,185
Security deposit	4,230	0
Total Current Assets	526,160	657,537
Operating lease right of use asset	12,988	25,719
Security deposit	0	4,230
TOTAL ASSETS	539,148	687,486
Current Liabilities
Accounts payable and accrued expenses	87,536	76,571
Deferred revenue	20,000	20,000
Due to related parties	78,970	78,826
Operating lease liabilities - current	12,988	25,719
Total Current and Total Liabilities	199,494	201,116
Stockholders' Equity
Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding	0	0
Common stock: 100,000,000 authorized; $0.001 par value; 60,042,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022	60,042	60,042
Additional paid-in capital	32,296,813	32,295,236
Deferred stock compensation	(1,009,433)	(8,060,983)
Accumulated deficit	(31,007,768)	(23,807,925)
Total Stockholders' Equity	339,654	486,370
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 539,148	$ 687,486

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Balance Sheets
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares Issued	60,042,000	60,042,000
Common Stock, Shares Outstanding	60,042,000	60,042,000

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statements of Operations (Unaudited)
Revenues	$ 0	$ 0	$ 0	$ 298,500
Cost of revenues	0	0	0	222,000
Gross profit	0	0	0	76,500
Operating expenses
Selling, general and administrative	1,316,425	1,476,432	2,799,991	2,961,520
Research and development	1,878,275	2,520,000	4,398,275	5,040,000
Total operating expenses	3,194,700	3,996,432	7,198,266	8,001,520
Loss from operations	(3,194,700)	(3,996,432)	(7,198,266)	(7,925,020)
Other expense
Interest expense - related party	789	211	1,577	420
Total other expenses	789	211	1,577	420
Loss before income tax expense	(3,195,489)	(3,996,643)	(7,199,843)	(7,925,440)
Income tax expense	0	0	0	0
Net loss	$ (3,195,489)	$ (3,996,643)	$ (7,199,843)	$ (7,925,440)
Basic and diluted loss per share of common stock	$ (0.05)	$ (0.07)	$ (0.12)	$ (0.13)
Weighted average number of shares of common stock outstanding	60,042,000	60,042,000	60,042,000	60,042,000

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Deferred stock compensation	Accumulated Deficit
Balance, shares at Dec. 31, 2021		60,042,000
Balance, amount at Dec. 31, 2021	$ 643,707	$ 60,042	$ 0	$ 32,293,530	$ (23,773,383)	$ (7,936,482)
Amortization of deferred stock compensation	3,928,100	0	0	0	3,928,100	0
Imputed interest on related party loans	209	0	0	209	0	0
Net loss	(3,928,797)	$ 0	0	0	0	(3,928,797)
Balance, shares at Mar. 31, 2022		60,042,000
Balance, amount at Mar. 31, 2022	643,219	$ 60,042	0	32,293,739	(19,845,283)	(11,865,279)
Balance, shares at Dec. 31, 2021		60,042,000
Balance, amount at Dec. 31, 2021	643,707	$ 60,042	0	32,293,530	(23,773,383)	(7,936,482)
Amortization of deferred stock compensation	7,856,200
Net loss	(7,925,440)
Balance, shares at Jun. 30, 2022		60,042,000
Balance, amount at Jun. 30, 2022	574,887	$ 60,042	0	32,293,950	(15,917,183)	(15,861,922)
Balance, shares at Mar. 31, 2022		60,042,000
Balance, amount at Mar. 31, 2022	643,219	$ 60,042	0	32,293,739	(19,845,283)	(11,865,279)
Amortization of deferred stock compensation	3,928,100	0	0	0	3,928,100	0
Imputed interest on related party loans	211	0	0	211	0	0
Net loss	(3,996,643)	$ 0	0	0	0	(3,996,643)
Balance, shares at Jun. 30, 2022		60,042,000
Balance, amount at Jun. 30, 2022	574,887	$ 60,042	0	32,293,950	(15,917,183)	(15,861,922)
Balance, shares at Dec. 31, 2022		60,042,000
Balance, amount at Dec. 31, 2022	486,370	$ 60,042	0	32,295,236	(8,060,983)	(23,807,925)
Amortization of deferred stock compensation	3,928,100	0	0	0	3,928,100	0
Imputed interest on related party loans	788	0	0	788	0	0
Net loss	(4,004,354)	$ 0	0	0	0	(4,004,354)
Balance, shares at Mar. 31, 2023		60,042,000
Balance, amount at Mar. 31, 2023	410,904	$ 60,042	0	32,296,024	(4,132,883)	(27,812,279)
Balance, shares at Dec. 31, 2022		60,042,000
Balance, amount at Dec. 31, 2022	486,370	$ 60,042	0	32,295,236	(8,060,983)	(23,807,925)
Amortization of deferred stock compensation	7,051,550
Net loss	(7,199,843)
Balance, shares at Jun. 30, 2023		60,042,000
Balance, amount at Jun. 30, 2023	339,654	$ 60,042	0	32,296,813	(1,009,433)	(31,007,768)
Balance, shares at Mar. 31, 2023		60,042,000
Balance, amount at Mar. 31, 2023	410,904	$ 60,042	0	32,296,024	(4,132,883)	(27,812,279)
Amortization of deferred stock compensation	3,123,450	0	0	0	3,123,450	0
Imputed interest on related party loans	789	0	0	789	0	0
Net loss	(3,195,489)	$ 0	0	0	0	(3,195,489)
Balance, shares at Jun. 30, 2023		60,042,000
Balance, amount at Jun. 30, 2023	$ 339,654	$ 60,042	$ 0	$ 32,296,813	$ (1,009,433)	$ (31,007,768)

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,199,843)	$ (7,925,440)
Adjustments to reconcile net loss to net cash used in operating activities:
Imputed interest - related parties	1,577	420
Amortization of deferred stock compensation	7,051,550	7,856,200
Changes in operating assets and liabilities:
Accounts receivable	140,000	299,500
Inventories	0	(296,000)
Prepaid expenses	(7,565)	(7,128)
Accounts payable and accrued expenses	10,965	(11,197)
Net cash used in operating activities	(3,316)	(83,645)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from related parties	144	504
Net cash provided by financing activities	144	504
Net change in cash	(3,172)	(83,141)
Cash at beginning of period	5,852	95,248
Cash at end of period	2,680	12,107
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest	$ 0	$ 0

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2023
ORGANIZATION AND DESCRIPTION OF BUSINESS
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd. The Company’s business is the sale of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine. During the second and third quarters of 2021, the Company engaged consultants to take the initial steps to develop and implement a research and development and marketing program. These consultants are working independently and report to the chief executive officer. As of the date of this report, the research and development efforts have not developed any products, the contracts with the consultants either expired in May 2023 or will expire in August 2023, and the Company does not expect that any new product, new marketing opportunities or revenue will result from such marketing and research and development efforts.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited Interim Financial Statements The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2022 have been omitted; and these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the year ended December 31, 2022 included within the Company’s annual report on Form 10-K for the year ended December 31, 2022. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. Revenue Recognition We recognize revenue in accordance with Topic 606, which requires revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. Under these criteria, the Company generally recognizes revenue when its products are delivered to customers in accordance with the written sales terms. Cash received in advance from customers is recorded as deferred revenue. Accounts Receivable Accounts receivable are recorded in accordance with ASC 310, “Receivables.” Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company does not currently have any amount recorded as an allowance for doubtful accounts. Based on management’s estimate, the Company has not deemed it necessary to reserve for doubtful accounts at this time. Net Income (Loss) Per Share of Common Stock The Company has adopted ASC Topic 260, “ Earnings per Share”

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2023
GOING CONCERN
GOING CONCERN	NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had nominal cash as of June 30, 2023, had no revenue in the first and second quarters of 2023 and incurred a loss from operations for the six months ended June 30, 2023 and has incurred losses for the past few years. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company proposes to fund operations through sales of its products and equity financing arrangements. However, because of the lack of sales and the absence of any active trading market for its common stock, its financial condition and its lack of an operating history, the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements and will have to rely on advances from a minority stockholder and its officer. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	6 Months Ended
	Jun. 30, 2023
RELATED PARTY TRANSACTIONS AND BALANCES
RELATED PARTY TRANSACTIONS AND BALANCES	NOTE 4 - RELATED PARTY TRANSACTIONS AND BALANCES During the six months ended June 30, 2023 and 2022, a minority stockholder who is not a 5% stockholder paid expenses of $144 and $504 on behalf of the Company, respectively. During the three months ended June 30, 2023 and 2022, such minority stockholder paid expenses of $108 and $216 on behalf of the Company, respectively. At June 30, 2023 and December 31, 2022, the Company owed $77,870 and $77,726 to the minority stockholder referred to in the preceding paragraph for non-interest-bearing advances made to or paid expenses on behalf of the Company, and are due on demand, respectively. At June 30, 2023 and December 31, 2022, the Company owed $1,100 to its CEO for non-interest-bearing advances made to or paid expenses on behalf of the Company and are due on demand. The Company has imputed interest at the rate of 4% on the advances made to or paid expenses on behalf of the Company in the amount of $1,577 and $420 during the six months ended June 30, 2023 and 2022, respectively and in the amount of $789 and $211 during the three months ended June 30, 2023 and 2022, respectively.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2023
LEASES
LEASES	NOTE 5 - LEASES On November 3, 2021, the Company entered into a lease agreement to rent a storage facility in Hong Kong for a two-year term at HK$17,000 (approximately $2,190) per month and paid HK$33,000 (approximately $4,230) as a security deposit. In accordance with ASC 842, the Company recognized operating lease ROU assets and lease liabilities, which had balances as follows: June 30, December 31, 2023 2022 Operating lease ROU asset $ 12,988 $ 25,719 June 30, December 31, 2023 2022 Operating lease liabilities – all current portion $ 12,988 $ 25,719 Future minimum lease payments under operating leases at June 30, 2023, were as follows: Remainder of 2023 $ 13,140 2024 and thereafter - Total $ 13,140 The Company recognized total lease expenses of $13,140 and $13,140 for the six months ended June 30, 2023 and 2022, respectively and of $6,570 and $6,570 for the three months ended June 30, 2023 and 2022, respectively.

STOCKHOLDERS EQUITY

STOCKHOLDERS EQUITY	6 Months Ended
	Jun. 30, 2023
STOCKHOLDERS EQUITY
STOCKHOLDERS' EQUITY	NOTE 6 – STOCKHOLDERS' EQUITY The Company issued a total of 6,776,000 and 5,506,000 shares of common stock to consultants as stock grants pursuant to two-year consulting agreements with the consultants entered into in May 2021 and August 2021, respectively, of which 11,912,000 shares were issued pursuant to the 2020 equity incentive plan (the “Plan”) and 370,000 were issued as restricted stock grants outside of the Plan. The agreements provide for the consultants to perform services described in the contracts for the two-year period commencing May 25, 2021 and August 23, 2021. The shares were valued at $19,311,600 and $12,113,200, based on the market price of the common stock on the respective dates of the agreements, which was $2.85 and $2.20 per share, respectively, and is being amortized over the two-year period starting from the date of agreement using the straight-line method. During the six months ended June 30, 2023 and 2022, the Company recorded stock-based compensation of $7,051,550 and $7,856,200, respectively, and during the three months ended June 30, 2023 and 2022, the Company recorded stock-based compensation of $3,123,450 and $3,928,100, respectively. The Company had deferred stock compensation of $1,009,433 and $8,060,983 as of June 30, 2023 and December 31, 2022, respectively, which will be recognized over the balance of the agreements, which terminate in the third quarter of 2023.

CONCENTRATION

CONCENTRATION	6 Months Ended
	Jun. 30, 2023
CONCENTRATION
CONCENTRATION	NOTE 7 - CONCENTRATION Revenue During the three and six months ended June 30, 2023, the Company did not generate revenue. During the three and six months ended June 30, 2022, all revenue was derived from one customer which was generated during the first quarter of 2022. Purchases During the three and six months ended June 30, 2023, the Company did not purchase inventory. During the three and six months ended June 30, 2022, all purchases were made from one supplier. Accounts receivable As of June 30, 2023 and December 31, 2022, the Company has accounts receivable consisting of customer A 72% and 56% and customer B 28% and 44%, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2023
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of the issuance of these unaudited financial statements and determined that no subsequent event requires recognition or disclosure to the unaudited financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Unaudited Interim Financial Statements	The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2022 have been omitted; and these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the year ended December 31, 2022 included within the Company’s annual report on Form 10-K for the year ended December 31, 2022. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.
Revenue Recognition	We recognize revenue in accordance with Topic 606, which requires revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. Under these criteria, the Company generally recognizes revenue when its products are delivered to customers in accordance with the written sales terms. Cash received in advance from customers is recorded as deferred revenue.
Accounts Receivable	Accounts receivable are recorded in accordance with ASC 310, “Receivables.” Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company does not currently have any amount recorded as an allowance for doubtful accounts. Based on management’s estimate, the Company has not deemed it necessary to reserve for doubtful accounts at this time.
Net Income (Loss) Per Share of Common Stock	The Company has adopted ASC Topic 260, “ Earnings per Share”

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2023
LEASES
Schedule of Operating Lease ROU Assets and Lease Liabilities	June 30, December 31, 2023 2022 Operating lease ROU asset $ 12,988 $ 25,719 June 30, December 31, 2023 2022 Operating lease liabilities – all current portion $ 12,988 $ 25,719
Schedule of operating future minimum lease payments	Remainder of 2023 $ 13,140 2024 and thereafter - Total $ 13,140

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Detail Narrative)	6 Months Ended
	Jun. 30, 2023
ORGANIZATION AND DESCRIPTION OF BUSINESS
Discription of contracts	the contracts with the consultants either expired in May 2023 or will expire in August 2023

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Imputed Interest - Related Parties			$ 1,577	$ 420
Stockholder [Member]
Due To Officers Or Stockholders	$ 77,870		77,870		$ 77,726
Related Party Transaction, Expenses	$ 108	$ 216	$ 144	504
Related Party Transaction, Rate	5%		5%
Percentage Of Inputed Interest			4%
Imputed Interest - Related Parties	$ 789	$ 211	$ 1,577	$ 420
Chief Executive Officer [Member]
Due To Officers Or Stockholders	$ 1,100		$ 1,100		$ 1,100

LEASES (Details)

LEASES (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
LEASES
Operating lease ROU asset	$ 12,988	$ 25,719

LEASES (Details 1)

LEASES (Details 1) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
LEASES
Operating lease liabilities - all current portion	$ 12,988	$ 25,719

LEASES (Details 2)

LEASES (Details 2)	Jun. 30, 2023 USD ($)
LEASES
Remainder 2023	$ 13,140
2024 and thereafter	0
Total	$ 13,140

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Nov. 03, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total Lease Expenses		$ 6,570	$ 6,570	$ 13,140	$ 13,140
Lease Agreement [Member] | Hong Kong [Member]
Security Deposit	$ 4,230
Rent Expenses	$ 2,190
Lease Term	two-year

STOCKHOLDERS EQUITY (Details Na

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Restricted Stock Grants Issued	$ 370,000		$ 370,000
Deferred Stock Compensation	1,009,433		1,009,433		$ 8,060,983
Stock Based Compensation Expenses	$ 3,123,450	$ 3,928,100	$ 7,051,550	$ 7,856,200
2020 Equity Incentive Plan [Member]
Common Stock Share Stock Grants	11,912,000		11,912,000
Agreements Description			The agreements provide for the consultants to perform services described in the contracts for the two-year period commencing May 25, 2021 and August 23, 2021
August 23, 2021 [Member]
Common Stock Share Stock Grants, Value	$ 12,113,200		$ 12,113,200
Common Stock Shares Price Per Share	$ 2.20		$ 2.20
Common Stock Share Stock Grants, Share			5,506,000
May 25, 2021 [Member]
Common Stock Shares Price Per Share	$ 2.85		$ 2.85
Common Stock Share Stock Grants, Share			6,776,000
Common Stock Share Stock Grants, Value	$ 19,311,600		$ 19,311,600

CONCENTRATION (Details Narrativ

CONCENTRATION (Details Narrative)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2021
Revenue [Member] | Customer B
Concentration credit risk	28%	44%
Revenue [Member] | Customer A
Concentration credit risk	72%	56%
Revenue [Member] | Customer concentration risk [Member]
Concentration risk, customer	one customer
Purchase [Member] | Customer concentration risk [Member]
Concentration risk, customer	one supplier